FDA lifts hold on Pluristem trial; shares rise
This article was originally published in Clinica
Executive Summary
Shares of Pluristem Therapeutics rose as much as 8.7% on 16 September after the company revealed the US FDA had lifted its clinical hold on the firm's Phase II study of experimental placenta-based cell therapy, PLX-PAD, in intermittent claudication (IC) – with the agency declaring the firm had satisfactorily addressed all issues raised by regulators.